Adam B. Francisco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adam B. Francisco has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Praveen Sethupathy
Cornell University
15 shared publications Lola M. Reid
14 shared publicationsMatt Kanke
14 shared publicationsBo Shui
13 shared publicationsJian Liu
13 shared publicationsJine Li
13 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
CSGALNACT1 is dramatically upregulated in FLC. A, A schematic showing the sequence of events leading to heparan and chondroitin synthesis. B, Differential expression of EXTL2, EXT1, EXT2, and NDST1 is shown as normalized counts in FLC (n = 23) and NML (n = 4). C, Differential expression of CSGALNACT1, CSGALNACT2, CHPF, and CHSY1 is shown as normalized counts in FLC (n = 23) and NML (n = 4). D,CSGALNACT1 expression relative to EXTL2 expression is shown as a ratio of normalized counts in FLC (n = 23) and NML (n = 4). E, Quantitative PCR showing the relative quantitative value (RQV) of CSGALNACT1 in a separate cohort of FLC samples (n = 11) compared with NML samples (n = 5). F, Quantitative PCR showing the RQV of CSGALNACT1 in a subset of FLC samples (n = 4) that have matched NML tissue. The matched NML/FLC samples are indicated with a line linking the two data points. *, P < 0.05; **, P < 0.01; ***, P < 0.001, two-tailed Student t test.
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
CSGALNACT1 is dramatically upregulated in FLC. A, A schematic showing the sequence of events leading to heparan and chondroitin synthesis. B, Differential expression of EXTL2, EXT1, EXT2, and NDST1 is shown as normalized counts in FLC (n = 23) and NML (n = 4). C, Differential expression of CSGALNACT1, CSGALNACT2, CHPF, and CHSY1 is shown as normalized counts in FLC (n = 23) and NML (n = 4). D,CSGALNACT1 expression relative to EXTL2 expression is shown as a ratio of normalized counts in FLC (n = 23) and NML (n = 4). E, Quantitative PCR showing the relative quantitative value (RQV) of CSGALNACT1 in a separate cohort of FLC samples (n = 11) compared with NML samples (n = 5). F, Quantitative PCR showing the RQV of CSGALNACT1 in a subset of FLC samples (n = 4) that have matched NML tissue. The matched NML/FLC samples are indicated with a line linking the two data points. *, P < 0.05; **, P < 0.01; ***, P < 0.001, two-tailed Student t test.
- Open Access
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
CS disaccharide abundance is significantly increased in FLC. A, A schematic diagram detailing disaccharide extraction and identification. B, Nanograms of CS (3) per milligram of dry tissue in FLC (n = 11) and NML (n = 5) tissue. C, Nanograms of non-sulfated CS (CS di-0S) per milligram of dry tissue in FLC (n = 11) and NML (n = 5) tissue. D, Nanograms of HS per milligram of dry tissue in FLC (n = 4) and NML (n = 2) tissue. *, P < 0.05, two-tailed Student t test.
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
CS disaccharide abundance is significantly increased in FLC. A, A schematic diagram detailing disaccharide extraction and identification. B, Nanograms of CS (3) per milligram of dry tissue in FLC (n = 11) and NML (n = 5) tissue. C, Nanograms of non-sulfated CS (CS di-0S) per milligram of dry tissue in FLC (n = 11) and NML (n = 5) tissue. D, Nanograms of HS per milligram of dry tissue in FLC (n = 4) and NML (n = 2) tissue. *, P < 0.05, two-tailed Student t test.
- Open Access
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
FIGURE 6 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
Activity at the VCAN locus is high in both tumor epithelial and activated stellate cells in FLC. A, UMAP dimensional reduction showing eight cell clusters found in primary FLC, metastatic FLC, and NML tissue (∼9,500 nuclei). B, Single-nucleus analysis of chromatin accessibility near the CSGALNACT1 locus. Increasing signal is indicated by the color gradient (maximum signal is yellow and minimal signal is dark blue). C, Genome tracks showing the location of open chromatin near the CSGALNACT1 locus in each cell type. The annotated transcriptional start site for CSGALNACT1 is shown at the bottom of the panel. D, Single-nucleus analysis of chromatin accessibility near the VCAN locus. Increasing signal is indicated by the color gradient (maximum signal is yellow and the minimal signal is dark blue. E, Genome tracks showing the location of open chromatin signal near the VCAN locus in each cell type. The annotated transcriptional start site for VCAN is shown at the bottom of the panel. Cell clusters are denoted through color coding: NML hepatocytes in light blue, FLC primary tumor transformed epithelial cells in orange, FLC metastatic tumor transformed epithelial cells in red, NML cholangiocytes in yellow, FLC primary and metastatic activated stellate cells in dark blue, FLC primary and metastatic immune cells in dark purple, FLC primary and metastatic endothelial cells in green, and NML immune and endothelial cells in light purple.
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 6 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
Activity at the VCAN locus is high in both tumor epithelial and activated stellate cells in FLC. A, UMAP dimensional reduction showing eight cell clusters found in primary FLC, metastatic FLC, and NML tissue (∼9,500 nuclei). B, Single-nucleus analysis of chromatin accessibility near the CSGALNACT1 locus. Increasing signal is indicated by the color gradient (maximum signal is yellow and minimal signal is dark blue). C, Genome tracks showing the location of open chromatin near the CSGALNACT1 locus in each cell type. The annotated transcriptional start site for CSGALNACT1 is shown at the bottom of the panel. D, Single-nucleus analysis of chromatin accessibility near the VCAN locus. Increasing signal is indicated by the color gradient (maximum signal is yellow and the minimal signal is dark blue. E, Genome tracks showing the location of open chromatin signal near the VCAN locus in each cell type. The annotated transcriptional start site for VCAN is shown at the bottom of the panel. Cell clusters are denoted through color coding: NML hepatocytes in light blue, FLC primary tumor transformed epithelial cells in orange, FLC metastatic tumor transformed epithelial cells in red, NML cholangiocytes in yellow, FLC primary and metastatic activated stellate cells in dark blue, FLC primary and metastatic immune cells in dark purple, FLC primary and metastatic endothelial cells in green, and NML immune and endothelial cells in light purple.
- Open Access
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
FIGURE 7 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
Model for the relevance of CS and VCAN in FLC. A schematic showing the behaviors of nonmalignant hepatocytes, quiescent and activated stellate cells, and endothelial cells with respect to CS and VCAN during FLC progression.
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 7 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
Model for the relevance of CS and VCAN in FLC. A schematic showing the behaviors of nonmalignant hepatocytes, quiescent and activated stellate cells, and endothelial cells with respect to CS and VCAN during FLC progression.
- Open Access
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
Monosulfated CS disaccharide abundance is significantly increased in FLC. A, A schematic diagram detailing CS di-4S. B, Differential expression of CHST11 is shown as normalized counts in FLC (n = 23) and NML (n = 4). C, Nanograms of CS di-4S per milligram of dry tissue in FLC (n = 11) and NML (n = 5) tissue. D, A schematic diagram detailing CS di-6S. E, Differential expression of CHST3 is shown as normalized counts in FLC (n = 23) and NML (n = 4). F, Nanograms of CS di-6S per milligram of dry tissue in FLC (n = 11) and NML (n = 5) tissue. G, A schematic diagram detailing CS di-4S6S. H, Differential expression of CHST15 is shown as normalized counts in FLC (n = 23) and NML (n = 4). I, Nanograms of CS di-4S6S per milligram of dry tissue in FLC (n = 11) and NML (n = 5) tissue. J, A schematic diagram detailing CS di-2S4S. K, Differential expression of UST is shown as normalized counts in FLC (n = 23) and NML (n = 4). L, Nanograms of CS di-2S4S per milligram of dry tissue in FLC (n = 11) and NML (n = 5) tissue. *, P < 0.05, two-tailed Student t test.
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
Monosulfated CS disaccharide abundance is significantly increased in FLC. A, A schematic diagram detailing CS di-4S. B, Differential expression of CHST11 is shown as normalized counts in FLC (n = 23) and NML (n = 4). C, Nanograms of CS di-4S per milligram of dry tissue in FLC (n = 11) and NML (n = 5) tissue. D, A schematic diagram detailing CS di-6S. E, Differential expression of CHST3 is shown as normalized counts in FLC (n = 23) and NML (n = 4). F, Nanograms of CS di-6S per milligram of dry tissue in FLC (n = 11) and NML (n = 5) tissue. G, A schematic diagram detailing CS di-4S6S. H, Differential expression of CHST15 is shown as normalized counts in FLC (n = 23) and NML (n = 4). I, Nanograms of CS di-4S6S per milligram of dry tissue in FLC (n = 11) and NML (n = 5) tissue. J, A schematic diagram detailing CS di-2S4S. K, Differential expression of UST is shown as normalized counts in FLC (n = 23) and NML (n = 4). L, Nanograms of CS di-2S4S per milligram of dry tissue in FLC (n = 11) and NML (n = 5) tissue. *, P < 0.05, two-tailed Student t test.
- Open Access
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
CSAP VCAN is aberrant in FLC. A, Differential expression of VCAN, CD44, and CSPG4 is shown as normalized counts in FLC (n = 23) and NML (n = 4). B, Quantitative PCR showing the RQV of VCAN in a separate cohort of FLC samples (n = 11) compared with NML samples (n = 5). C, Quantitative PCR showing the RQV of VCAN in a subset of FLC samples that have matched NML tissue (n = 4). The matched NML/FLC samples are indicated with a line linking the two data points. D, Immunoblot in matched FLC/NML samples (n = 3) showing VCAN in the lower and vinculin in the top. E, VCAN protein levels normalized to vinculin levels are shown as RQV. The matched NML/FLC samples are indicated with a line linking the two data points. F, IHF of VCAN protein in two independent patient-matched tissue samples is shown in green. Nuclei are blue. Scale bar, 100 μm. *, P < 0.05; **, P < 0.01; ***, P < 0.001, two-tailed Student t test.
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
CSAP VCAN is aberrant in FLC. A, Differential expression of VCAN, CD44, and CSPG4 is shown as normalized counts in FLC (n = 23) and NML (n = 4). B, Quantitative PCR showing the RQV of VCAN in a separate cohort of FLC samples (n = 11) compared with NML samples (n = 5). C, Quantitative PCR showing the RQV of VCAN in a subset of FLC samples that have matched NML tissue (n = 4). The matched NML/FLC samples are indicated with a line linking the two data points. D, Immunoblot in matched FLC/NML samples (n = 3) showing VCAN in the lower and vinculin in the top. E, VCAN protein levels normalized to vinculin levels are shown as RQV. The matched NML/FLC samples are indicated with a line linking the two data points. F, IHF of VCAN protein in two independent patient-matched tissue samples is shown in green. Nuclei are blue. Scale bar, 100 μm. *, P < 0.05; **, P < 0.01; ***, P < 0.001, two-tailed Student t test.
- Open Access
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
CSGALNACT1 and VCAN are more highly upregulated in FLC than in almost all other cancers and correlate with DNAJB1-PRKACA levels. A, Normalized counts of CSGALNACT1 expression in RNA-seq datasets available for 25 tumor types in TCGA. B, Normalized counts of VCAN expression in RNA-seq datasets available for 25 tumor types in TCGA. C, Correlation between CSGALNACT1 (y-axis) and VCAN (x-axis) shown as the relative quantitative values from qPCR in a separate cohort of FLC samples (n = 11). D, Correlation between DNAJB1-PRKACA (y-axis) and VCAN (x-axis) shown as the relative quantitative values from qRT-PCR in FLC samples (n = 11). E, Correlation between DNAJB1-PRKACA (y-axis) to CSGALNACT1 (x-axis) shown as the relative quantitative values from qRT-PCR in FLC samples (n = 11). ACC, adenoid cystic carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; FCL, fibrolamellar carcinoma samples analyzed in this study; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal papillary cell carcinoma; KIRP, kidney renal clear cell carcinoma; LAML, acute myeloid leukemia; LGG, lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
- 9 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
CSGALNACT1 and VCAN are more highly upregulated in FLC than in almost all other cancers and correlate with DNAJB1-PRKACA levels. A, Normalized counts of CSGALNACT1 expression in RNA-seq datasets available for 25 tumor types in TCGA. B, Normalized counts of VCAN expression in RNA-seq datasets available for 25 tumor types in TCGA. C, Correlation between CSGALNACT1 (y-axis) and VCAN (x-axis) shown as the relative quantitative values from qPCR in a separate cohort of FLC samples (n = 11). D, Correlation between DNAJB1-PRKACA (y-axis) and VCAN (x-axis) shown as the relative quantitative values from qRT-PCR in FLC samples (n = 11). E, Correlation between DNAJB1-PRKACA (y-axis) to CSGALNACT1 (x-axis) shown as the relative quantitative values from qRT-PCR in FLC samples (n = 11). ACC, adenoid cystic carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; FCL, fibrolamellar carcinoma samples analyzed in this study; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal papillary cell carcinoma; KIRP, kidney renal clear cell carcinoma; LAML, acute myeloid leukemia; LGG, lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
- Open Access
Coenzyme A is a redox sensing cofactor for malic enzyme 2 regulating oxidative stress and mitochondrial metabolism
Coenzyme A (CoA) is an essential cofactor required for numerous metabolic reactions, yet its ability to bind and regulate proteins remains poorly defined. Using a proteomic approach, we identified malic enzyme 2 (ME2) as a CoA-binding protein. ME2 uses NAD(P) + to convert malate to pyruvate, generating NAD(P)H to support energy production and redox homeostasis. ME2 binds CoA at an allosteric site previously thought to bind NAD(P) + . Reduced CoA has minimal effect on ME2 activity, but the oxidized form, CoA disulfide, strongly activates ME2 by promoting ME2 tetramerization and a catalytically efficient closed conformation. Under oxidative stress, ME2 facilitates CoA disulfide formation, enhancing NADPH production and cellular defense against reactive oxygen species (ROS). Mice with ME2 mutation that cannot bind CoA show impaired muscle performance, elevated ROS, and mitochondrial dysfunction. These findings establish CoA as a redox-sensing cofactor, allowing cells to respond to ROS and promote mitochondrial metabolism, and expanding the function of this essential cofactor.
Open AccessCoenzyme A is a redox sensing cofactor for malic enzyme 2 regulating oxidative stress and mitochondrial metabolism
Coenzyme A (CoA) is an essential cofactor required for numerous metabolic reactions, yet its ability to bind and regulate proteins remains poorly defined. Using a proteomic approach, we identified malic enzyme 2 (ME2) as a CoA-binding protein. ME2 uses NAD(P) + to convert malate to pyruvate, generating NAD(P)H to support energy production and redox homeostasis. ME2 binds CoA at an allosteric site previously thought to bind NAD(P) + . Reduced CoA has minimal effect on ME2 activity, but the oxidized form, CoA disulfide, strongly activates ME2 by promoting ME2 tetramerization and a catalytically efficient closed conformation. Under oxidative stress, ME2 facilitates CoA disulfide formation, enhancing NADPH production and cellular defense against reactive oxygen species (ROS). Mice with ME2 mutation that cannot bind CoA show impaired muscle performance, elevated ROS, and mitochondrial dysfunction. These findings establish CoA as a redox-sensing cofactor, allowing cells to respond to ROS and promote mitochondrial metabolism, and expanding the function of this essential cofactor.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figures S1-S5 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
All supplemental figures with legends.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figures S1-S5 from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
All supplemental figures with legends.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
Fibrolamellar carcinoma (FLC) is an aggressive liver cancer with no effective therapeutic options. The extracellular environment of FLC tumors is poorly characterized and may contribute to cancer growth and/or metastasis. To bridge this knowledge gap, we assessed pathways relevant to proteoglycans, a major component of the extracellular matrix. We first analyzed gene expression data from FLC and nonmalignant liver tissue (n = 27) to identify changes in glycosaminoglycan (GAG) biosynthesis pathways and found that genes associated with production of chondroitin sulfate, but not other GAGs, are significantly increased by 8-fold. We then implemented a novel LC/MS-MS based method to quantify the abundance of different types of GAGs in patient tumors (n = 16) and found that chondroitin sulfate is significantly more abundant in FLC tumors by 6-fold. Upon further analysis of GAG-associated proteins, we found that versican (VCAN) expression is significantly upregulated at the mRNA and protein levels, the latter of which was validated by IHC. Finally, we performed single-cell assay for transposase-accessible chromatin sequencing on FLC tumors (n = 3), which revealed for the first time the different cell types in FLC tumors and also showed that VCAN is likely produced not only from FLC tumor epithelial cells but also activated stellate cells. Our results reveal a pathologic aberrancy in chondroitin (but not heparan) sulfate proteoglycans in FLC and highlight a potential role for activated stellate cells.Significance:This study leverages a multi-disciplinary approach, including state-of-the-art chemical analyses and cutting-edge single-cell genomic technologies, to identify for the first time a marked chondroitin sulfate aberrancy in FLC that could open novel therapeutic avenues in the future.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma
Fibrolamellar carcinoma (FLC) is an aggressive liver cancer with no effective therapeutic options. The extracellular environment of FLC tumors is poorly characterized and may contribute to cancer growth and/or metastasis. To bridge this knowledge gap, we assessed pathways relevant to proteoglycans, a major component of the extracellular matrix. We first analyzed gene expression data from FLC and nonmalignant liver tissue (n = 27) to identify changes in glycosaminoglycan (GAG) biosynthesis pathways and found that genes associated with production of chondroitin sulfate, but not other GAGs, are significantly increased by 8-fold. We then implemented a novel LC/MS-MS based method to quantify the abundance of different types of GAGs in patient tumors (n = 16) and found that chondroitin sulfate is significantly more abundant in FLC tumors by 6-fold. Upon further analysis of GAG-associated proteins, we found that versican (VCAN) expression is significantly upregulated at the mRNA and protein levels, the latter of which was validated by IHC. Finally, we performed single-cell assay for transposase-accessible chromatin sequencing on FLC tumors (n = 3), which revealed for the first time the different cell types in FLC tumors and also showed that VCAN is likely produced not only from FLC tumor epithelial cells but also activated stellate cells. Our results reveal a pathologic aberrancy in chondroitin (but not heparan) sulfate proteoglycans in FLC and highlight a potential role for activated stellate cells.Significance:This study leverages a multi-disciplinary approach, including state-of-the-art chemical analyses and cutting-edge single-cell genomic technologies, to identify for the first time a marked chondroitin sulfate aberrancy in FLC that could open novel therapeutic avenues in the future.